Cunbo Ma

Cunbo Ma

Auto-generated profile, based on publicly available information

Cunbo Ma

Department of Medicinal Chemistry, Jacobio Pharmaceuticals Co., Ltd., Beijing, China

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 August 2024 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
CMCunbo Ma
Cunbo Ma
DKDi Kang
Di Kang
PGPanliang Gao
Panliang Gao
WZWei Zhang
Wei Zhang
XWXinping Wu
Xinping Wu
WLWei Long
Wei Long

7 May 2025 in Clinical Cancer Research
Verified
Journal Article
Closed access
DKDi Kang
Di Kang
YWYanping Wang
Yanping Wang
YLYiwei Lin
Yiwei Lin
WMWen Wee Ma
Wen Wee Ma
DMDaniel Morgensztern
Daniel Morgensztern
YWYinxiang Wang
Yinxiang Wang
Purpose: Recent advances have seen the development of targeted therapeutics against the receptor tyrosine kinase (RTK)/RAS/MAPK pathway, which, when aberrantly activated, drives the malignant transformation of many cancer indications. However, the efficacy of inhibitors targeting single molecules is dampened by pathway feedback activation and acquired drug resistance. We seek to evaluate the application of JAB-3312 (sitneprotafib), a potent inhibitor of SHP2, in RTK/RAS/MAPK pathway–targeted combination therapies. Furthermore, SHP2 plays a vital role in PD-1–mediated immunosuppression. The rational combination of JAB-3312 with PD-1 blocking therapies is also explored. Experimental Design: Biochemical and cellular assays were applied to evaluate the potency of JAB-3312 in SHP2 inhibition. Tumor cell lines and cell line– and patient-derived xenografts were used to test different combinations of JAB-3312 with KRASG12C, MEK, EGFR, and PD-1 inhibitors. Results: JAB-3312 produced potent in vitro inhibition of SHP2 activity and downstream ERK phosphorylation, with IC50 values of 1.44 nmol/L and 0.68 to 4.84 nmol/L, respectively. When used in combination, JAB-3312 significantly increased the antitumor activity of the KRASG12C inhibitor glecirasib in naïve and resistant models. The combination of JAB-3312 with MEK inhibitors significantly delayed RTK signaling reactivation and enhanced tumor growth inhibition in KRAS-mutated cancer models. The JAB-3312–osimertinib combination exhibited great efficacy in osimertinib-resistant non–small cell lung cancer models. Additionally, JAB-3312 enhanced the efficacy of PD-1 blockade therapies by promoting an antitumor microenvironment. Representative cases of patients who responded to the combination therapies from two ongoing clinical trials (NCT05288205 and NCT04720976) were reported. Conclusions: JAB-3312 in combination with RTK/RAS/MAPK or PD-1 blockade therapies is a promising strategy that warrants further clinical investigation.

15 July 2025
Verified
Other
Open access
DKDi Kang
Di Kang
YWYanping Wang
Yanping Wang
YLYiwei Lin
Yiwei Lin
WMWen Wee Ma
Wen Wee Ma
DMDaniel Morgensztern
Daniel Morgensztern
YWYinxiang Wang
Yinxiang Wang
Supplementary Figure S6. The combination of JAB-3312 and EGFR inhibitor osimertinib synergistically inhibited cancer cell growth in vitro and did not affect the weight gain of mice. A-B. Proliferation inhibition of NCI-H1975 (A) and NCI-H1975-C797S (B) human lung cancer cells by JAB-3312, osimertinib, or their combination. C-D. The body weight change of NCI-H1975 (C) and LUN#2355-214 (D) xenograft models during the treatment of JAB-3312, osimertinib, and the two-drug combination. Mean ± SEM was shown.

15 July 2025
Verified
Other
Open access
DKDi Kang
Di Kang
YWYanping Wang
Yanping Wang
YLYiwei Lin
Yiwei Lin
WMWen Wee Ma
Wen Wee Ma
DMDaniel Morgensztern
Daniel Morgensztern
YWYinxiang Wang
Yinxiang Wang
Supplementary Figure S2. The combination of JAB-3312 and glecirasib can enhance the inhibitory effect on the growth of KRASG12C mutant tumors in vitro and in vivo. A. Proliferation inhibition of SW837 human colon cancer cells by JAB-3312, glecirasib, or their combination. B-E. The tumor volume change of SW837 (B), MIA PaCa-2 (C), CR6243 (D), and CR6256 (E) xenograft models during the treatment of JAB-3312, glecirasib, and the two-drug combination. Mean tumor volumes ± SEM were shown.

15 July 2025
Verified
Other
Open access
DKDi Kang
Di Kang
YWYanping Wang
Yanping Wang
YLYiwei Lin
Yiwei Lin
WMWen Wee Ma
Wen Wee Ma
DMDaniel Morgensztern
Daniel Morgensztern
YWYinxiang Wang
Yinxiang Wang
Supplementary Table S3. Representativeness of study participants.

15 July 2025
Verified
Other
Open access
DKDi Kang
Di Kang
YWYanping Wang
Yanping Wang
YLYiwei Lin
Yiwei Lin
WMWen Wee Ma
Wen Wee Ma
DMDaniel Morgensztern
Daniel Morgensztern
YWYinxiang Wang
Yinxiang Wang
Purpose:Recent advances have seen the development of targeted therapeutics against the receptor tyrosine kinase (RTK)/RAS/MAPK pathway, which, when aberrantly activated, drives the malignant transformation of many cancer indications. However, the efficacy of inhibitors targeting single molecules is dampened by pathway feedback activation and acquired drug resistance. We seek to evaluate the application of JAB-3312 (sitneprotafib), a potent inhibitor of SHP2, in RTK/RAS/MAPK pathway–targeted combination therapies. Furthermore, SHP2 plays a vital role in PD-1–mediated immunosuppression. The rational combination of JAB-3312 with PD-1 blocking therapies is also explored.Experimental Design:Biochemical and cellular assays were applied to evaluate the potency of JAB-3312 in SHP2 inhibition. Tumor cell lines and cell line– and patient-derived xenografts were used to test different combinations of JAB-3312 with KRASG12C, MEK, EGFR, and PD-1 inhibitors.Results:JAB-3312 produced potent in vitro inhibition of SHP2 activity and downstream ERK phosphorylation, with IC50 values of 1.44 nmol/L and 0.68 to 4.84 nmol/L, respectively. When used in combination, JAB-3312 significantly increased the antitumor activity of the KRASG12C inhibitor glecirasib in naïve and resistant models. The combination of JAB-3312 with MEK inhibitors significantly delayed RTK signaling reactivation and enhanced tumor growth inhibition in KRAS-mutated cancer models. The JAB-3312–osimertinib combination exhibited great efficacy in osimertinib-resistant non–small cell lung cancer models. Additionally, JAB-3312 enhanced the efficacy of PD-1 blockade therapies by promoting an antitumor microenvironment. Representative cases of patients who responded to the combination therapies from two ongoing clinical trials (NCT05288205 and NCT04720976) were reported.Conclusions:JAB-3312 in combination with RTK/RAS/MAPK or PD-1 blockade therapies is a promising strategy that warrants further clinical investigation.